{
    "clinical_study": {
        "@rank": "13101", 
        "arm_group": [
            {
                "arm_group_label": "Endostar -Continued Pumping into+GP", 
                "arm_group_type": "Experimental", 
                "description": "Endostar that is Continued Pumping into vein Combining With Gemcitabine -Cisplatin"
            }, 
            {
                "arm_group_label": "Endostar -injecting into +GP", 
                "arm_group_type": "Active Comparator", 
                "description": "Endostar that is injecting into vein with Gemcitabine -Cisplatin"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether Endostar pumping into vein with\n      Gemcitabine-Cisplatin are more effective than Endostar with Gemcitabine-Cisplatin regularly\n      in the treatment of Non-Small Cell Lung Cancer (NSCLC)."
        }, 
        "brief_title": "Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Endostar have anti-tumor activity by against vascular endothelial growth factor for initial\n      treatment. This study was designed to evaluate the safety and efficacy of Endostar Continued\n      vein-pumping Combining with Gemcitabine-Cisplatin  (GP)chemotherapy in patients with\n      NSCLC,and seeking for more effective injection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically or cytologically diagnosed NSCLC;\n\n          2. primary treatment,inoperable stage IIIB/IV NSCLC;\n\n          3. Age of 18-75years; Gender Not Required;\n\n          4. Adequate hematologic, renal, and hepatic function ,Specific index as follows:\n\n             liver function: S-Bilirubin \u22641.5 ULN ; Transaminase\u22642 ULN. renal function:\n             S-Creatinine \u22641.2 ULN; blood urea nitrogen \u22641.2 ULN . ULN: upper normal limit. Marrow\n             Hemopoietic Function: WBC\u22654.0\u00d710^9/l, ANC\u22652.0\u00d710^9/l platelet count \u2265100\u00d710^9/l,\n             Hb\u2265100 g/l;\n\n          5. ECOG PS 0-2,Life expectancy \u2265 3 months; endure more than two cycle chemotherapy;\n\n          6. The patients have explicit lung tumor lesions and the lesions were measurable;\n             (According to the standard of RECIST1.1, they should have at least one of accurately\n             measurable lesions with the largest diameter \u2265 10mm by spiral CT, MRI);\n\n          7. No history of serious drug allergy;\n\n          8. Informed consent should be obtained before treatment.\n\n        Exclusion Criteria:\n\n          1. Symptomatic brain metastases with cognitive disorder,bone metastases with\n             complications;\n\n          2. Major organ dysfunction and Serious Heart Disease( congestive\n             heart-failure,incontrollable high-risk arrhythmia,unstable angina, valvular disease,\n             myocardial infarct and Resistant hypertension,);\n\n          3. Serious complications and investigator consider it is unsuited enrolling;\n\n          4. Pregnant or lactating women;\n\n          5. Allergic to research drug;\n\n          6. participating in other experimental trials and receive the treatment in four weeks;\n\n          7. The position that is for observing curative effect have a radiotherapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01669707", 
            "org_study_id": "BeijingCH001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Endostar -Continued Pumping into+GP", 
                "description": "Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 120 hours and the dosage is 7.5mg/m2*5 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-4cycles.", 
                "intervention_name": "Endostar -Continued Pumping into+GP", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Endostar -injecting into +GP", 
                "description": "Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-4cycles", 
                "intervention_name": "Endostar -injecting into +GP", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Endostar", 
            "advanced Non-small cell lung cancer", 
            "Continued Pumping into vein", 
            "Gemcitabine", 
            "Carboplatin"
        ], 
        "lastchanged_date": "August 17, 2012", 
        "location": {
            "contact": {
                "email": "xuliyan2009@yahoo.cn", 
                "last_name": "Liyan Xu, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "The Beijing Chest Hospital"
            }, 
            "investigator": {
                "last_name": "Liyan Xu, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)", 
        "overall_contact": {
            "email": "xuliyan2009@yahoo.cn", 
            "last_name": "Liyan Xu, MD"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival (PFS)", 
            "safety_issue": "Yes", 
            "time_frame": "two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01669707"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Beijing Chest Hospital", 
            "investigator_full_name": "Liyan Xu", 
            "investigator_title": "Chief of Medical Oncology Department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "Yes", 
                "time_frame": "two years"
            }, 
            {
                "measure": "Clinical benefit rate (CBR)", 
                "safety_issue": "Yes", 
                "time_frame": "two years"
            }, 
            {
                "measure": "Number of Participants With Adverse Events(AE) as a Measure of Safety and Tolerability", 
                "safety_issue": "No", 
                "time_frame": "two years"
            }
        ], 
        "source": "Beijing Chest Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing Chest Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}